Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Publishing of Stockmann’s Half year financial report for January–June 2022

STOCKMANN plc, Press release 19.7.2022 at 12:30 EET Stockmann plc will publish the Half year financial report for January–June 2022 on Friday, 22 July 2022 at 8:00 a.m. EET. The press and analyst briefing will be held on 22 July 2022 at 10:00 as a live webcast, that can be followed by this link . The recording and presentation material are available on the company's website after the event. Further information:Stockmann Media DeskMon–Fri 9–16 EETtel. +358 50 389 0011info@stockmann.com www.stockmanngroup.com

Repurchase of NCC Series B shares in week 28, 2022

During the period July 11 – July 15, 2022, NCC (LEI-code 213800WRGLW3CY4MHW53) repurchased a total of 341,533 own Series B shares (ISIN: SE0000117970) under the framework of the repurchase program that the Board have decided.The repurchases are part of the repurchase program of a maximum of 10 percent of Series B shares for a total of not more than SEK 1.5 bn that NCC announced on April 27, 2022. The repurchase program extends from May 11, 2022 until the 2023 Annual General Meeting and is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 (“MAR”) and the

Buy-back of shares in MTG during week 28, 2022

During the period between 11 July – 15 July 2022 Modern Times Group MTG AB (publ) (LEI code 549300E8NDODRSX29339) (“MTG”) has repurchased, in total, 183,159 own class B shares (ISIN code SE0000412371) under the share repurchase program initiated by the Board of Directors as part of the commitment to return money to shareholders and to simultaneously optimize the capital structure of the company.The share buy-backs form a part of the share repurchase program of a maximum of 4,018,414 shares for a maximum amount of SEK 200 million, which MTG announced on 17 June 2022. The share repurchase

RugVista strengthens sustainability work through membership in Textile Exchange

RugVista today announced that the company has become a member of Textile Exchange, a global non-profit organization that works to reduce the textile industry's environmental impact. RugVista has, as previously announced, also had the company's climate goals approved by the Science Based Target initiative. These memberships are an important part of achieving RugVista's sustainability goals of reducing the company's greenhouse gas emissions by 50% and increasing the proportion of natural, recycled, or reused materials to 80%, by 2030. "Sustainability is a fundamental part of RugVista's

Swedbank Mortgage’s interim report for the first half of 2022 published

Swedbank Mortgage’s interim report for the first half of 2022 has been published at www.swedbank.com/ir.   Swedbank Mortgage AB (in Swedish: Swedbank Hypotek) is a wholly owned subsidiary to Swedbank AB (publ). Mortgages are distributed through Swedbank’s and the Swedish savings banks branches as well as digital channels.   · Net interest income affected by lower margins · Higher net gains and losses · Continued good credit quality and very low loss levels · Solid capital position     Swedbank Mortgage AB (publ) is required to disclose this information

PostNord: Second quarter 2022

Second quarter 2022  · Net sales totaled SEK 10,037 million (10,323), a decrease of -5 percent (13) in fixed currency for like-for-like units  · Overall, parcel volumes decreased by -7 percent (14) due to lower business-to-consumer volumes  · Mail volumes decreased by -12 percent (-4).  · Operating income (EBIT) totaled SEK 214 million (518)Comments from Annemarie Gardshol, CEO Major actions taken to deal with a world that continues to present challenges The Group's sales amounted to SEK 10,037 million (10,323), representing a decrease of -5 percent from the same period

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 128 - 19 JULY 2022  In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, A/S Motortramp participates by selling shares pro rata in order to maintain the current ownership of just under 32% of the shares in Dampskibsselskabet NORDEN A/S. The market will be informed accordingly – see the attached file and announcement no. 117/2022.     Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Thomas France, Investor Communications Partner, tel.: 3315 0451

Interim report second quarter and first half of 2022

Second quarter 2022 · Order intake increased by 17% to SEK 7,029 million (6,006). For comparable units, it was an increase of 7%. · Net sales increased by 20% to SEK 6,683 million (5,552). For comparable units, it was an increase of 10%. · EBITA increased by 21% to SEK 1,023 million (843), corresponding to an EBITA margin of 15.3% (15.2%). · Profit for the quarter rose 20% to SEK 675 million (562), and earnings per share amounted to SEK 1.85 (1.54). · Cash flow from operating activities amounted to SEK 622 million (792). 1 January – 30 June 2022 · Order intake

Ericsson Imagine Possible Perspectives: how connectivity can change the world

· New Ericsson digital experience outlines likely major trends towards 2030 · Education, entertainment, enterprise and sustainability among the areas to benefit · Includes contributions from the Institute of the Future and the GSMAWhat can be achieved in just eight years? A new Ericsson (NASDAQ: ERIC) digital experience addresses how 5G and next-generation connectivity could make things that may be beyond our imagination today into everyday realities by 2030. Ericsson Imagine Possible Perspectives 

Publishing of Caverion Corporation's Half-year Financial Report for January−June 2022 on 4 August 2022

Caverion Corporation Investor News 19 July 2022 at 10.00 a.m. EESTPublishing of Caverion Corporation's Half-year Financial Report for January−June 2022 on 4 August 2022 Caverion Corporation's Half-year Financial Report for January−June 2022 will be published on Thursday, 4 August 2022, at approximately 8:00 a.m. (Finnish Time, EEST). The stock exchange release and presentation materials in Finnish and in English will be published at that time on the company's website at www.caverion.com/investors. News conference for investors and media Caverion will hold a news conference on the

Esmaeilzadeh Holding publishes net asset value as of 30 June 2022

As of 30 June 2022, net asset value for Esmaeilzadeh Holding AB (publ) (“the Company”) was SEK 7.65 billion, corresponding to a net asset value per share of SEK 10,097. The Company has published future occasions for publication of net asset value on the Company's website . For further information, please contact: Saeid Esmaeilzadeh, CEO and founder +46 707 18 70 61, saeid@ehab.group Nils Fredrik Dehlin, General Counsel & IR +46 720 90 26 99, nilsfredrik@ehab.group The information was submitted for

Sinch publishes updated historical segment reporting after implementation of new operating model

Stockholm, Sweden – July 19, 2022 – Sinch AB (publ), a global leader in cloud communications and mobile customer engagement, today announced that updated historical financial segment reporting has been made available on the company’s investor relations website investors.sinch.com. The publication of updated historical segment reporting is made to simplify the understanding of Sinch’s upcoming quarterly report, where the new segment reporting has been implemented. The updated segment reporting does not affect Sinch’s previously reported total revenues or profit. The new segments match

Truecaller was one of the 20 most downloaded apps during the second quarter

For the second quarter in a row, Truecaller, the leading global platform for verifying contacts and blocking unwanted communications, was one of the world's 20 most downloaded apps according to Sensor Tower's quarterly report "Q2 Store Intelligence Data Digest". According to the report, Truecaller was the fourteenth most downloaded app in Google Play during the second quarter.Sensor Towers report, which is available here , shows that Truecaller, for the second quarter in a row was one of the world's 20

Inhalation Sciences submits abstract to present landmark data from PreciseInhale clinical study at DDL 2022

(Stockholm 19 July 2022) ISAB has submitted an abstract to present data from its study validating PreciseInhale for clinical use, at the Drug Delivery to the Lungs (DDL) conference 2022 in Edinburgh, Scotland. The data demonstrate that PreciseInhale[®] outperformed standard commercial inhalers and improved ‘regional targeting’ of aerosols to specific areas of the lungs. DDL is one of the inhalation markets’ most influential events, with all major companies within the industry set to be present onsite, for the first time post-pandemic.At DDL 2022, 7- 9 December in Edinburgh, Scotland,

Interim report Q2/2022: Improved sales give confidence for the future

Significant Significant events after the quarterevents inQ2 · In · To secure long-time financing of the operations, the Board ofJune, Directors decided in July to raise about SEK 74.7 million throughEnzymatica a rights issue. The new issue is 100% guaranteed by subscriptionAB signed a commitments together with underwriting agreements from theloan company’s three largest shareholders, as well as the company’sagreement Chairman of the Board and CEO.with thethreelargestowners, aswell as thecompany’sCEO andchairman ofthe board,

Prevas interim report January – June 2022

Solid quarter with increased profitability. April-June 2022 · Net turnover 335.3 MSEK (313.2) · Operating profit/loss EBITA 34.9 MSEK (29.8) · Operating margin EBITA 10.4% (9.5) · Operating profit/loss EBIT 33.6 MSEK (28.9) · Operating margin EBIT 10.0% (9.2) · Profit after tax 28.7 MSEK (1.,5) · Profit per share before dilution 2.16 SEK (1.35) January-June 2022 · Net turnover 650.8 MSEK (614.1) · Operating profit/loss EBITA 79.1 MSEK (61.3) · Operating margin EBITA 12.2% (10.0) · Operating profit/loss EBIT 76.9 MSEK (59.6) · Operating

Obducat receives order valued at 16 million SEK from a customer in Europe

OBDUCAT AB (pub) subsidiary Obducat Europe GmbH, a leading supplier of system solutions for lithography processing, has received an order from a customer in Europe, for the supply of a fully automated and highly customized Wet Processing Tool. The order value amounts to approx. 16 million SEK. The order value will be included in the second quarter's order intake 2022. The tool will be installed in an existing semiconductor fab facility and will be used in a combined wet process- and wafer test application. Further information cannot be disclosed at this point in time. The tool will be

Interim Report 1 April – 30 June 2022

In summing up, we can declare a strong second quarter whose performance is one of the Group's most profitable for the April-June period ever. Operating profit came in at SEK 20 million, which is a great improvement and a clear indication that we are on the right track towards restoring profitability. Even when we exclude the support we received as a result of the restrictions, the Group's performance shows clear improvements in profitability. In this context, we note that the Covid-related restrictions from previous periods, combined with the unrest in the world at large, had a negative

Enhertu approved in EU for HER2-positive mBC

19 July 2022 07:00 BST Enhertu approved in the EU for patients with HER2-positive metastatic breast cancer treated with one or more prior anti-HER2-based regimens Approval broadens indication for AstraZeneca and Daiichi Sankyo's Enhertu across Europe to earlier use in HER2-positive metastatic breast cancer Based on ground-breaking DESTINY-Breast03 results in which Enhertu demonstrated a 72% reduction in the risk of disease progression or death vs. trastuzumab emtansine (T-DM1) AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the European

Enhertu approved in the EU for patients with HER2-positive metastatic breast cancer treated with one or more prior anti-HER2-based regimens

Approval broadens indication for AstraZeneca and Daiichi Sankyo’s Enhertu across Europe to earlier use in HER2-positive metastatic breast cancer. Based on ground-breaking DESTINY-Breast03 results in which Enhertu demonstrated a 72% reduction in the risk of disease progression or death vs. trastuzumab emtansine (T-DM1).AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based

Juuso Pajunen appointed as CFO of Terveystalo

Terveystalo Plc. Stock Exchange Release 19.7.2022 at 09:01 EEST Juuso Pajunen, b. 1981, M.Sc. (Econ.) has been appointed as Chief Financial Officer and member of the Executive team. Juuso Pajunen will start in the position in January 2023 the latest. Pajunen joins Terveystalo from AFRY, an engineering and consulting company, where he currently holds the position of CFO. Prior to his current position, Pajunen held multiple senior financial positions at Pöyry Group, including CFO and the Head of Group Business Control.  “I’m delighted to announce appointment of Juuso Pajunen as our

Embellence Group Interim Report Q2 2022

Navigating towards our long-term goalSecond quarter 2022 · Net sales amounted to MSEK 189.9 (160.0), up 18.7%. · Negative organic growth of -4.0%. · Adjusted EBITA* amounted to MSEK 24.4 (22.9), up 6.6%. · EBITA amounted to MSEK 22.0 (21.2), up 3.8%. · Net profit for the period** amounted to MSEK 2.0 (13.3), and earnings per share for the period before dilution were SEK 0.09 (0.62). · Operating cash flow amounted to MSEK 26.5 (17.8). *EBITA excluding acquisition costs related to the acquisition of Artscape, as well as restructuring costs in the Nordics.**Net profit

Getinge Interim Report January-June 2022: Recovery in elective surgery overshadowed by external challenges

“Order intake and net sales declined organically by 5% and 7.5% respectively in the quarter, which however ended with increased order intake,” says Mattias Perjos, President & CEO. ”Our customers are planning for a normal flu season in the second half of the year, which is expected to result in a recovery in ICU products”.The performance for the quarter as a whole was impacted by reduced production of COVID-19 vaccines and the number of patients requiring life support in Intensive Care Units (ICUs) declining significantly more than both the health care sector and Getinge had predicted,

Interim report 1 January – 30 June 2022

Halmstad, 19 July 2022SECOND QUARTER (1 April – 30 June 2022) · Net sales for the quarter amounted to MSEK 53 (36). · Operating profit before depreciation and amortisation (EBITDA) totalled MSEK 25 (12). · Operating profit (EBIT) was MSEK 10 (-6). · Profit/loss before tax, before items affecting comparability, was MSEK 7 (-10) and after items affecting comparability MSEK -6 (-6). · Profit/loss after tax totalled MSEK -6 (-6), corresponding to SEK -0.13 (-0.16) per share. · Operating cash flow was MSEK 67 (12) and was impacted by an increase in current liabilities related

There are no items matching the current filter
There are no more items matching the current filter
Back to top